



IAP3 Rec'd PCT/PTO 1.9 DEC 2005

ATTORNEY DOCKET: 66535.000004

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/549,685 Confirmation No.: Unassigned
Applicant : Eva CAROFF, et al.
Filed : September 19, 2005
Title : GUANIDINE DERIVATIVES AND THEIR USE AS
NEUROPEPTIDE RECEPTOR ANTAGONISTS
TC/Art Unit : Unassigned
Examiner: : Unassigned

Docket No. : 66535.000004
Customer No. : 21967

MAIL STOP PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants submit the attached Form PTO/SB/08A (modified) for consideration and request the documents cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Several of the documents listed on the attached Form PTO/SB/08A (modified) were cited by the European Patent Office in the International Search Report, mailed on June 16, 2004, for International Application No. PCT/CH2004/000175 and in the International Search Report, mailed on August 26, 2003, for International Application No. CH4662003. Copies of the International Search Report for PCT/CH2004/000175 and CH4662003 are enclosed herein.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references, other than U.S. patents and U.S. patent publications, is enclosed

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.


Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action and within three months of the filing date of the application. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP


Dated: December 19, 2005

By: 
Robert M. Schulman
Registration No. 31,196

Alexander H. Spiegler
Registration No. 56,625

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
RMS/AHS/asc

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/549,685
Filing Date	September 19, 2005
First Named Inventor	Eva CAROFF, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	66535.000004

Sheet 1 of 5

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1.	4,624,956		Lazzarini, et al.	11-25-1986	
	2.	4,716,228		Scarponi, et al.	12-29-1987	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	3.	DE	2206385	C2	Dr. Karl Thomae GmbH	08-16-1973		
	4.	WO	02/24192	A1	Institut National De La Sante et De La Recherche Medicale	03-28-2002		
	5.	WO	04/083218	A1	Actelion Pharmaceuticals Ltd.	09-30-2004		
	6.	GB	1,140,387		Dr. Karl Thomae GmbH	01-15-1969		
	7.	EP	0 321 191		Pfizer, Inc.	06-21-1989		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8.	YANG, et al., "Isolation, Sequencing, Synthesis, and Pharmacological Characterization of Two Brain Neuropeptides that Modulate the Action of Morphine", PNAS, Vol. 82, pgs. 7757-7761, 1985.	
	9.	ROUMY, et al., "Neuropeptide FF, Pain and Analgesia", European Journal of Pharmacology, Vol. 345, pgs. 1-11, 1998.	
	10.	PANULA, et al., "Neuropeptide FF, A Mammalian Neuropeptide with Multiple Functions", Progress in Neurobiology, Vol. 48, pgs. 461-487, 1996.	
	11.	LAKE, et al., "IgG from Neuropeptide FF Antiserum Reverses Morphine Tolerance in the Rat", Neuroscience Letters, Vol. 132, pgs. 29-32, 1991.	

Examiner Signature	/Manu Manohar/	Date Considered	09/28/2008
-----------------------	----------------	--------------------	------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/549,685
Filing Date	September 19, 2005
First Named Inventor	Eva CAROFF, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	66535.000004

Sheet 2 of 5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12.	ELSHOURBAGY, et al., "Receptor for the Pain Modulatory Neuropeptides FF and AF is an Orphan G Protein-coupled Receptor", The Journal of Biological Chemistry, Vol. 275, No. 34, pgs. 25965-25971, 2000.	
	13.	SUNDBLOM, et al., "Pulsatile Secretion of Neuropeptide FF into Human Blood", Peptides, Vol. 19, No. 7, pgs. 1165-1170, 1998.	
	14.	BONINI, et al., "Identification and Characterization of Two G Protein-coupled Receptors for Neuropeptide FF", The Journal of Biological Chemistry, Vol. 275, No. 50, pgs. 39324-39331, 2000.	
	15.	KOTANI, et al., "Functional Characterization of a Human Receptor for Neuropeptide FF and Related Peptides", British Journal of Pharmacology, Vol. 133, pgs. 138-144, 2001.	
	16.	ALLARD, et al., "Characterization of Rat Spinal Cord Receptors to FLFQPRFamide, a Mammalian Morphine Modulating Peptide: A Binding Study", Brain Research, Vol. 500, pgs. 169-176, 1989.	
	17.	ALLARD, et al., "Autoradiographic Distribution of Receptors to FLFQPRFamide, a Morphine-Modulating Peptide, in Rat Central Nervous System", Neuroscience, Vol. 49, No. 1, pgs. 101-116, 1992.	
	18.	GOUARDERES, et al., "Quantitative Autoradiographic Distribution of NPFF ₁ Neuropeptide FF Receptor in the Rat Brain and Comparison with NPFF ₂ Receptor by Using [¹²⁵ I]YVP and [¹²⁵ I]EYF as Selective Radioligands", Neuroscience, Vol. 115, No. 2, pgs. 349-361, 2002.	
	19.	LIU, et al., "Identification and Characterization of Novel Mammalian Neuropeptide FF-like Peptides that Attenuate Morphine-Induced Antinociception", The Journal of Biological Chemistry, Vol. 276, No. 40, pgs. 36961-36969, 2001.	
	20.	LEFRERE, et al., "Neuropeptide AF and FF Modulation of Adipocyte Metabolism", The Journal of Biological Chemistry, Vol. 277, No. 42, pgs. 39169-39178, 2002.	
	21.	MALIN, et al., "Analog of Neuropeptide FF Attenuates Morphine Abstinence Syndrome", Peptides, Vol. 12, pgs. 1011-1014, 1991.	
	22.	PROKAI, et al., "Combinatorial Lead Optimization of a Neuropeptide FF Antagonist", J. Med. Chem., Vol. 44, pgs. 1623-1626, 2001.	

Examiner
Signature

/Manu Manohar/

Date

Considered

09/28/2008


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/549,685
Filing Date	Septemebr 19, 2005
First Named Inventor	Eva CAROFF, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	66535.000004

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23.	MOLLEREAU, et al., "Pharmacological Characterization of Human NPFF ₁ and NPFF ₂ Receptors Expressed in CHO Cells by Using NPY Y ₁ Receptor Antagonists", European Journal of Pharmacology, Vol. 451, pgs. 245-256, 2002.	
	24.	QUELVEN, et al., "Dissociation of Pharmacological Pro- and Anti-opioid Effects by Neuropeptide FF Analogs", European Journal of Pharmacology, Vol. 449, pgs. 91-98, 2002.	
	25.	SCHNUR, et al., "N-(5-Fluorobenzothiazol-2-yl)-2-guanidinethiazole-4-carboxamide. A Novel, Systemically Active Antitumor Agent Effective Against 3LL Lewis Lung Carcinoma", J. Med. Chem., Vol. 34, pgs. 914-918, 1991.	
	26.	TANAKA, et al., "Antiplatelet Agents Based on Cyclooxygenase Inhibition without Ulcerogenesis. Evaluation and Synthesis of 4,5-Bis(4-methoxyphenyl)-2-substituted-thiazoles", J. Med. Chem., Vol. 37, pgs. 1189-1199, 1994.	
	27.	YOKOO, et al., "Synthesis of 1-Azacycloheptan-4-one Hydrochloride", Studies on Seven-membered Heterocyclic Compounds Containing Nitrogen. I., Vol. 29, No. 5, pgs. 631-632, 1956.	
	28.	BERTZ, et al., "Organocopper Reagents in Dimethyl Sulfide", Tetrahedron, Vol. 45, No. 2, pgs. 425-434, 1989.	
	29.	BRUMMOND, et al., "α-Chlorination of Ketones Using p-Toluenesulfonyl Chloride", Tetrahedron Letters, Vol. 40, pgs. 2231-2234, 1999.	
	30.	MIHOVILOVIC, et al., "Asymmetric Baeyer-Villiger Oxidations of 4-Mono- and 4,4-Disubstituted Cyclohexanones by Whole Cells of Engineered Escherichia coli", J. Org. Chem. Vol. 66, pgs. 733-738, 2001.	
	31.	BAIGRIE, et al., "Stereospecific Formation of Enolates from Reaction of Unsymmetrical Ketenes and Organolithium Reagents", J. Am. Chem. Soc., Vol. 107, No. 19, pgs. 5391-5396, 1985.	
	32.	DE JONGH, et al., "Synthesis of Polyspiro Compounds Consisting of Cyclohexane Rings", Tetrahedron, Vol. 20, pgs. 2553-2573, 1964.	
	33.	RADIOVOY, et al., "Reduction of Sulfonates and Aromatic Compounds with the NiCl ₂ ·2H ₂ O-Li-Arene (cat.) Combination", Tetrahedron, Vol. 55, pgs. 14479-14490, 1999.	

Examiner Signature	/Manu Manohar/	Date Considered	09/28/2008
--------------------	----------------	-----------------	------------


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/549,685
Filing Date	September 19, 2005
First Named Inventor	Eva CAROFF, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	66535.000004

Sheet 4 of 5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34.	RITTER, "Synthetic Transformations of Vinyl and Aryl Triflates", Synthesis, pgs. 735-762, 1993.	
	35.	MAGNUS, et al., "Application of the β -Azidonation Reaction to the Synthesis of the Antitumor Alkaloid (+)-Pancratistatin", Tetrahedron, Vol. 54, pgs. 15509-15524, 1998.	
	36.	REETZ, et al., "The Kharasch Reaction Revisited: CuX_3Li_2 -catalyzed Conjugate Addition Reactions of Grignard Reagents", Journal of Organometallic Chemistry, Vol. 502, pgs. C5-C7, 1995.	
	37.	PARKER, et al., "Enantioselective Synthesis of the Enyne A-Ring Synthon of the 1 α -Hydroxy Vitamins D", J. Org. Chem., Vol. 62, No. 19, pgs. 6692-6696, 1997.	
	38.	CAZAEU, et al., "A New Practical Synthesis of Silyl Enol Ethers. Part. I. From Simple Aldehydes and Ketones", Tetrahedron, Vol. 43, No. 9, pgs. 2075-2088, 1987.	
	39.	REETZ, et al., "tert-Alkylation of Ketones and Aldehydes", Angew. Chem. Int. Ed. Engl. Vol. 17, No. 1, pgs. 48-49, 1978.	
	40.	SIT, et al., "Novel Dihydropyrazine Analogues as NPY Antagonists", Bioorganic & Medicinal Chemistry Letters, Vol. 12, pgs. 337-340, 2002.	
	41.	VILIM, et al., "Gene for Pain Modulatory Neuropeptide NPFF: Induction in Spinal Cord by Noxious Stimuli", Molecular Pharmacology, Vol. 55, pg. 804-811, pgs. 1999.	
	42.	PERRY, et al., "A Human Gene Encoding Morphine Modulating Peptides Related to NPFF and FMRFamide", FEBS Letters, Vol. 409, pgs. 426-430, 1997.	
	43.	KONTINEN, et al., "Differential Modulation of α_2 -Adrenergic and μ -Opioid Spinal Antinociception by Neuropeptide FF", Peptides, Vol. 16, No. 5, pgs. 973-977, 1995.	
	44.	GOUARDERES, et al., "Antinociceptive Effects of Intrathecally Administered F8Famide and FMRFamide in the Rat", European Journal of Pharmacology, Vol. 237, pgs. 73-81, 1993.	

Examiner Signature	/Manu Manohar/	Date Considered	09/28/2008
--------------------	----------------	-----------------	------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.M./

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/549,685
Filing Date	September 19, 2005
First Named Inventor	Eva CAROFF, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	66535.000004

Sheet 5 of 5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	45.	SINGH, et al., "Synthesis & Mass Spectra of Some Substituted 2-(2'-Benzazolylamino) Pyrimidines", Indian Journal of Chemistry, Vol. 22B, pgs. 37-42, January 1983.	
	46.	PETERLIN-MASIC, et al., "A General Synthetic Approach to Novel Conformationally Restricted Arginine Side Chain Mimetics", Tetrahedron, Vol. 58, pgs. 1557-1563, 2002.	
	47.	SCARPONI, et al., "Bicyclic Compounds with Potential Antiulcer and/or Antisecretory Activity", Il Farmaco, Vol. 43, No. 7-8, pgs. 575-596, 1988.	
	48.	MARINKO, et al., "A Convenient Synthesis of 4-aminomethyl-4, 5, 6, 7-tetrahydro-1, 3-benzothiazole Arginine Side-Chain Mimetics", Tetrahedron Letters, Vol. 42, No. 50, pgs. 8911-8913, 2001.	
	49.	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio, retrieved from STN Database Accession No. 1986:168468 XP002249435, RN 92715-48-5, 101242-99-3, 101243-00-9, 101243-32-7 and 101701-49-9 & JP 60 226810 A, Ikeda Mohando Co., Ltd., November 12, 1985.	
	50.	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio, retrieved from STN Database Accession No. 1987:176383 XP002249436, RN 107880-36-4 and 10788-37-5 & JP 62 033158 A, Shionogi and Co., Ltd., February 13, 1987.	
	51.	Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio, retrieved from STN Database Accession No. 1986:168468 XP002249437, RN 188611-98-5 & JP 90 059258 A, Ono Pharmaceutical Co., March 4, 1997.	

Examiner
Signature

/Manu Manohar/

Date
Considered

09/28/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.